awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q45116933-4DAB42B6-30F2-49D4-97C0-1FB591569E8D
Q45116933-4DAB42B6-30F2-49D4-97C0-1FB591569E8D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q45116933-4DAB42B6-30F2-49D4-97C0-1FB591569E8D
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
P2860
Q45116933-4DAB42B6-30F2-49D4-97C0-1FB591569E8D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q45116933-4DAB42B6-30F2-49D4-97C0-1FB591569E8D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7286a8cc8d84c331479d8320223c58ed4e10e401
P2860
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].